4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-3-fluorobenzoic acid | 133052-41-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-3-fluorobenzoic acid
• 英文别名: 4-[(2-Butylbenzimidazol-1-yl)methyl]-3-fluorobenzoic acid
• CAS: 133052-41-2
• 化学式: C₁₉H₁₉FN₂O₂
• 分子量: 326.37
• InChiKey: RVUFFTNXNWRPIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,4-亚甲基二氧溴苯 在 sodium hydroxide 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-3-fluorobenzoic acid
  参考文献：
  名称：

  New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties and structure-activity relationships of 2-alkylbenzimidazole derivatives

  摘要：

  On the basis of an extension of the literature lead 1, a series of benzimidazoles have been synthesized and shown to be angiotensin II (AII) receptor antagonists. The structure-activity relationships of these new antagonists have been explored and the key binding interactions defined. Molecular mechanics calculations were carried out on analogues of imidazole AII antagonists and conformationally restricted analogues were synthesized. The benzimidazole antagonists displaced AII in binding studies in vitro with IC50 values in the range 10(-5)-10(-7) M and antagonized the hypertensive effects of AII in vivo (rats) following intravenous administration with ED50 values in the range of 5-20 mg/kg.

  DOI：

  10.1021/jm00083a011

文献信息

• Benz[4,5]imidazole-containing angiotensin antagonists
  申请人：Imperial Chemical Industries plc

  公开号：US05171748A1

  公开（公告）日：1992-12-15

  The invention concerns novel heterocyclic compounds of the formula I as defined herein and their physiologically acceptable salts, together with pharmaceutical compositions containing them. The heterocyclic compounds antagonize the actions of angiotensin II and are of value in treating diseases or medical conditions such as hypertension and congestive heart failure in warm-blooded animals. The invention further includes processes for the manufacture of the novel compounds and their use in medical treatment.

  这项发明涉及本文所定义的式I的新颖杂环化合物及其生理学上可接受的盐，以及含有它们的药物组合物。这些杂环化合物拮抗血管紧张素II的作用，在治疗温血动物的高血压和充血性心力衰竭等疾病或医疗状况方面具有价值。该发明还包括用于制造这些新化合物的工艺和它们在医疗治疗中的应用。
• Benzimidazole derivatives
  申请人：ZENECA LIMITED

  公开号：EP0399732A1

  公开（公告）日：1990-11-28

  The invention concerns heterocyclic compounds of the formula I (and their physiologically acceptable salts), together with pharmaceutical compositions containing them. The heterocyclic compounds antagonise the actions of angiotensin II and are of value in treating diseases or medical conditions such as hypertension and congestive heart failure in warm-blooded animals. The invention further includes processes for the manufacture of the compounds and their use in medical treatment.

  本发明涉及式 I 的杂环化合物（及其生理上可接受的盐类）以及含有它们的药物组合物。 (及其生理上可接受的盐）以及含有它们的药物组合物。这些杂环化合物能拮抗血管紧张素 II 的作用，对治疗温血动物的高血压和充血性心力衰竭等疾病或病症具有重要价值。本发明还包括化合物的制造工艺及其在医疗中的应用。
• US5171748A
  申请人：——

  公开号：US5171748A

  公开（公告）日：1992-12-15
• New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties and structure-activity relationships of 2-alkylbenzimidazole derivatives
  作者：Andrew P. Thomas、Christopher P. Allott、Keith H. Gibson、John S. Major、Brian B. Masek、Alec A. Oldham、Arnold H. Ratcliffe、David A. Roberts、Simon T. Russell、Douglas A. Thomason

  DOI：10.1021/jm00083a011

  日期：1992.3

  On the basis of an extension of the literature lead 1, a series of benzimidazoles have been synthesized and shown to be angiotensin II (AII) receptor antagonists. The structure-activity relationships of these new antagonists have been explored and the key binding interactions defined. Molecular mechanics calculations were carried out on analogues of imidazole AII antagonists and conformationally restricted analogues were synthesized. The benzimidazole antagonists displaced AII in binding studies in vitro with IC50 values in the range 10(-5)-10(-7) M and antagonized the hypertensive effects of AII in vivo (rats) following intravenous administration with ED50 values in the range of 5-20 mg/kg.